Big Pharma Says Drug Prices Reflect R&D Cost. Researchers Call BS
At the end of September, a spot of good news: Relyvrio, a new drug for treating amyotrophic lateral sclerosisor ALS, a neurological disorder without a curewas approved in the United States. The ALS c… [read more]